Delivery Order SPE2DR25D9225-SPE2DR26FFAZ1
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 30, 2025, for Nuplazid 34 mg capsules (30-count packaging) valued at $10,375.53. This firm fixed-price delivery order, which carries no set-aside designation, represents a specific fulfillment under the company's broader Indefinite Delivery Contract with DLA. The contract will be completed by November...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $47,085.84 by the Defense Logistics Agency for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on January 8, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, indicating the company competed in open procurement. This award is issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count). This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $10,375.53 by the Defense Logistics Agency on July 18, 2025, for the supply of Nuplazid 34 mg capsules (30-count units). This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, carries no set-aside designation and will be performed at the contractor's Park Ridge, Illinois location. The award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc. for 30 capsules of Nuplazid 34 mg on November 28, 2025. This firm fixed-price delivery order, issued without set-aside designation, will be performed in Park Ridge, Illinois, with an ultimate completion date of December 19, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Illinois, serves as the sole awardee and has been...
- The Defense Logistics Agency issued a delivery order valued at $11,771.46 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on January 9, 2026. This firm fixed-price delivery order, which carries an ultimate completion date of February 2, 2026, represents a pharmaceutical supply transaction without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned...
- The Defense Logistics Agency awarded a $10,588.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $3,529.63 to DMS Pharmaceutical Group Inc. for 30-count bottles of Nuplazid 34 mg capsules, with a completion date of January 15, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order represents a firm fixed-price purchase issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packaging). This firm fixed-price delivery order, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packages). The award, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, utilizes firm fixed-price pricing and does not include a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- SPE2DR25D9225Indefinite Delivery Contract
- SPE2DR25D9225-SPE2DR26FFAZ1Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on January 9, 2026, by the Defense Logistics Agency for the supply of Nuplazid 34 mg capsules in a 30-count package. This firm fixed-price delivery order, valued at $11,771.46, represents one of numerous orders issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency. The award carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order is scheduled for ultimate completion by February 2, 2026, with performance to be conducted at the contractor's facility in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract designated SPE2DR within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that became effective in November 2025. The PPV-G GEN V program authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's contract under this vehicle, valued at up to $499.999 billion through December 31, 2036, positions the company as a critical regional pharmaceutical supplier for federal military medical system operations. The company's extensive product portfolio and demonstrated performance on multiple delivery orders underscore its capability to fulfill diverse pharmaceutical requirements across military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 1/8/26 |